Dec 6 (Reuters) - GlaxoSmithKline and Theravance Inc said on Friday that their combination therapy met the main goal of improving lung function in asthma patients in a late-stage trial.
By David Zanoni: This article features four stocks that have FDA decision dates in December 2013. The approval of the drugs in question should add increased revenue for the developing companies and further diversify their portfolio of drugs. Considerable amounts of time and money are invested by ...
As expected, GlaxoSmithKline ( GSK +0.2% ) and Theravance 's ( THRX -0.6% ) Relvar Ellipta gets European marketing ..... news triggers a $15M milestone payment to GSK from THRX . Another $15M will come due upon launch. ( PR
LONDON, Nov 18 (Reuters) - GlaxoSmithKline and Theravance 's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive pulmonary disease (COPD), confirming...
remaining 23% of assets are invested in small- and mid-cap pharmaceutical firms such as Mylan MYL, Salix SLXP, and Theravance THRX ; the U.S.' largest pharmaceutical firms trade on the New York Stock Exchange. IBB's index is one of eight
By John Vincent : This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's U.S. stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 11/13/2013. Please visit our Tracking Seth Klarman's Baupost Group Holdings ...
Theravance ( THRX ) discloses its TD-9855 drug did not meet the primary efficacy endpoint in Phase 2 study in adult patients with ADHD/hyperactivity
Theravance , Inc. ( THRX ) Credit Suisse Healthcare Conference ..... records. Our next company presenting is Theravance . It’s been a truly transformative ..... Winningham, who is the Chairman and CEO of Theravance and to his right is Mike Aguiar
By Fusion Research : On October 22, 2013, Novartis ( NVS ) declared its third quarter result; its revenue grew by 4% year over year to $14.34 billion, while its core EPS declined 4% to $1.26. Its two divisions, Sandoz and Consumer Healthcare, reported strong double-digit growth year over year, thus
a chronic disease that makes it hard for an individual to breathe. GlaxoSmithKline ( GSK ) has collaborated with Theravance ( THRX ) and has recently come up with a drug once again to treat this disease. COPD -prevalence of the disease in the